Cargando…

Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility

NF-κB2/p100 (p100) is an inhibitor of κB (IκB) protein that is partially degraded to produce the NF-κB2/p52 (p52) transcription factor. Heterozygous NFKB2 mutations cause a human syndrome of immunodeficiency and autoimmunity, but whether autoimmunity arises from insufficiency of p52 or IκB function...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirasinha, Rushika C., Davies, Ainsley R., Srivastava, Monika, Sheridan, Julie M., Sng, Xavier Y.X., Delmonte, Ottavia M., Dobbs, Kerry, Loh, Khai L., Miosge, Lisa A., Lee, Cindy Eunhee, Chand, Rochna, Chan, Anna, Yap, Jin Yan, Keller, Michael D., Chen, Karin, Rossjohn, Jamie, La Gruta, Nicole L., Vinuesa, Carola G., Reid, Hugh H., Lionakis, Michail S., Notarangelo, Luigi D., Gray, Daniel H.D., Goodnow, Christopher C., Cook, Matthew C., Daley, Stephen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595743/
https://www.ncbi.nlm.nih.gov/pubmed/33107914
http://dx.doi.org/10.1084/jem.20200476
_version_ 1783601944493817856
author Wirasinha, Rushika C.
Davies, Ainsley R.
Srivastava, Monika
Sheridan, Julie M.
Sng, Xavier Y.X.
Delmonte, Ottavia M.
Dobbs, Kerry
Loh, Khai L.
Miosge, Lisa A.
Lee, Cindy Eunhee
Chand, Rochna
Chan, Anna
Yap, Jin Yan
Keller, Michael D.
Chen, Karin
Rossjohn, Jamie
La Gruta, Nicole L.
Vinuesa, Carola G.
Reid, Hugh H.
Lionakis, Michail S.
Notarangelo, Luigi D.
Gray, Daniel H.D.
Goodnow, Christopher C.
Cook, Matthew C.
Daley, Stephen R.
author_facet Wirasinha, Rushika C.
Davies, Ainsley R.
Srivastava, Monika
Sheridan, Julie M.
Sng, Xavier Y.X.
Delmonte, Ottavia M.
Dobbs, Kerry
Loh, Khai L.
Miosge, Lisa A.
Lee, Cindy Eunhee
Chand, Rochna
Chan, Anna
Yap, Jin Yan
Keller, Michael D.
Chen, Karin
Rossjohn, Jamie
La Gruta, Nicole L.
Vinuesa, Carola G.
Reid, Hugh H.
Lionakis, Michail S.
Notarangelo, Luigi D.
Gray, Daniel H.D.
Goodnow, Christopher C.
Cook, Matthew C.
Daley, Stephen R.
author_sort Wirasinha, Rushika C.
collection PubMed
description NF-κB2/p100 (p100) is an inhibitor of κB (IκB) protein that is partially degraded to produce the NF-κB2/p52 (p52) transcription factor. Heterozygous NFKB2 mutations cause a human syndrome of immunodeficiency and autoimmunity, but whether autoimmunity arises from insufficiency of p52 or IκB function of mutated p100 is unclear. Here, we studied mice bearing mutations in the p100 degron, a domain that harbors most of the clinically recognized mutations and is required for signal-dependent p100 degradation. Distinct mutations caused graded increases in p100-degradation resistance. Severe p100-degradation resistance, due to inheritance of one highly degradation-resistant allele or two subclinical alleles, caused thymic medullary hypoplasia and autoimmune disease, whereas the absence of p100 and p52 did not. We inferred a similar mechanism occurs in humans, as the T cell receptor repertoires of affected humans and mice contained a hydrophobic signature of increased self-reactivity. Autoimmunity in autosomal dominant NFKB2 syndrome arises largely from defects in nonhematopoietic cells caused by the IκB function of degradation-resistant p100.
format Online
Article
Text
id pubmed-7595743
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-75957432021-08-01 Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility Wirasinha, Rushika C. Davies, Ainsley R. Srivastava, Monika Sheridan, Julie M. Sng, Xavier Y.X. Delmonte, Ottavia M. Dobbs, Kerry Loh, Khai L. Miosge, Lisa A. Lee, Cindy Eunhee Chand, Rochna Chan, Anna Yap, Jin Yan Keller, Michael D. Chen, Karin Rossjohn, Jamie La Gruta, Nicole L. Vinuesa, Carola G. Reid, Hugh H. Lionakis, Michail S. Notarangelo, Luigi D. Gray, Daniel H.D. Goodnow, Christopher C. Cook, Matthew C. Daley, Stephen R. J Exp Med Article NF-κB2/p100 (p100) is an inhibitor of κB (IκB) protein that is partially degraded to produce the NF-κB2/p52 (p52) transcription factor. Heterozygous NFKB2 mutations cause a human syndrome of immunodeficiency and autoimmunity, but whether autoimmunity arises from insufficiency of p52 or IκB function of mutated p100 is unclear. Here, we studied mice bearing mutations in the p100 degron, a domain that harbors most of the clinically recognized mutations and is required for signal-dependent p100 degradation. Distinct mutations caused graded increases in p100-degradation resistance. Severe p100-degradation resistance, due to inheritance of one highly degradation-resistant allele or two subclinical alleles, caused thymic medullary hypoplasia and autoimmune disease, whereas the absence of p100 and p52 did not. We inferred a similar mechanism occurs in humans, as the T cell receptor repertoires of affected humans and mice contained a hydrophobic signature of increased self-reactivity. Autoimmunity in autosomal dominant NFKB2 syndrome arises largely from defects in nonhematopoietic cells caused by the IκB function of degradation-resistant p100. Rockefeller University Press 2020-10-27 /pmc/articles/PMC7595743/ /pubmed/33107914 http://dx.doi.org/10.1084/jem.20200476 Text en © 2020 Wirasinha et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Wirasinha, Rushika C.
Davies, Ainsley R.
Srivastava, Monika
Sheridan, Julie M.
Sng, Xavier Y.X.
Delmonte, Ottavia M.
Dobbs, Kerry
Loh, Khai L.
Miosge, Lisa A.
Lee, Cindy Eunhee
Chand, Rochna
Chan, Anna
Yap, Jin Yan
Keller, Michael D.
Chen, Karin
Rossjohn, Jamie
La Gruta, Nicole L.
Vinuesa, Carola G.
Reid, Hugh H.
Lionakis, Michail S.
Notarangelo, Luigi D.
Gray, Daniel H.D.
Goodnow, Christopher C.
Cook, Matthew C.
Daley, Stephen R.
Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility
title Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility
title_full Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility
title_fullStr Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility
title_full_unstemmed Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility
title_short Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility
title_sort nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595743/
https://www.ncbi.nlm.nih.gov/pubmed/33107914
http://dx.doi.org/10.1084/jem.20200476
work_keys_str_mv AT wirasinharushikac nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT daviesainsleyr nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT srivastavamonika nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT sheridanjuliem nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT sngxavieryx nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT delmonteottaviam nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT dobbskerry nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT lohkhail nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT miosgelisaa nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT leecindyeunhee nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT chandrochna nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT chananna nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT yapjinyan nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT kellermichaeld nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT chenkarin nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT rossjohnjamie nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT lagrutanicolel nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT vinuesacarolag nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT reidhughh nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT lionakismichails nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT notarangeloluigid nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT graydanielhd nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT goodnowchristopherc nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT cookmatthewc nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility
AT daleystephenr nfkb2variantsrevealap100degradationthresholdthatdefinesautoimmunesusceptibility